Swedish Orphan Biovitrum (SOBI.ST) Stock Analysis & AI Equity Report
Swedish Orphan Biovitrum (SOBI.ST) overview
Swedish Orphan Biovitrum (SOBI.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Swedish Orphan Biovitrum reported revenue of SEK 28,238m and operating profit of SEK 8,048m; the year-end share price was 332.80 SEK and market capitalisation was SEK 114,583m. Swedish Orphan Biovitrum is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Swedish Orphan Biovitrum's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is a global biopharmaceutical company focused on rare diseases. It develops and commercialises medicines across haematology, immunology and specialty care, with products and programmes for conditions including haemophilia, immune thrombocytopenia, PNH and several rare genetic disorders. The company also emphasises expanding access to approved therapies in international markets.
Generate the Swedish Orphan Biovitrum report
Swedish Orphan Biovitrum is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Swedish Orphan Biovitrum and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.